Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.090
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
May 08, 2024
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
April 29, 2024
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
April 22, 2024
Via
ACCESSWIRE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
April 18, 2024
Via
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
April 09, 2024
Via
ACCESSWIRE
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
April 08, 2024
Via
ACCESSWIRE
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
April 02, 2024
Via
ACCESSWIRE
Jaguar Health Reports 2023 Financial Results
April 01, 2024
Via
ACCESSWIRE
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
February 23, 2024
Via
ACCESSWIRE
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
February 12, 2024
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
March 27, 2024
Via
ACCESSWIRE
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
March 20, 2024
Via
ACCESSWIRE
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
February 15, 2024
Via
ACCESSWIRE
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
February 14, 2024
Via
ACCESSWIRE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
January 30, 2024
Via
ACCESSWIRE
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
January 29, 2024
Via
ACCESSWIRE
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
January 04, 2024
Via
ACCESSWIRE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
December 04, 2023
Via
ACCESSWIRE
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
November 30, 2023
Via
ACCESSWIRE
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
January 25, 2024
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
Via
ACCESSWIRE
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
December 11, 2023
Via
ACCESSWIRE
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
December 07, 2023
Via
ACCESSWIRE
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
December 06, 2023
Via
ACCESSWIRE
Jaguar Health Reports Third Quarter 2023 Financial Results
November 14, 2023
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
November 08, 2023
Via
ACCESSWIRE
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
November 21, 2023
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
Via
ACCESSWIRE
Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
November 09, 2023
Via
ACCESSWIRE
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
November 08, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.